Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;20(1):37-46.
doi: 10.1111/jns.12114.

Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia

Affiliations

Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia

Ellen M Lavoie Smith et al. J Peripher Nerv Syst. 2015 Mar.

Abstract

Vincristine, a critical component of combination chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL), can lead to vincristine-induced peripheral neuropathy (VIPN). Longitudinal VIPN assessments were obtained over 12 months from newly diagnosed children with ALL (N = 128) aged 1-18 years who received vincristine at one of four academic children's hospitals. VIPN assessments were obtained using the Total Neuropathy Score-Pediatric Vincristine (TNS©-PV), National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE©), Balis© grading scale, and Pediatric Neuropathic Pain Scale©-Five (PNPS©-5). Of children who provided a full TNS©-PV score, 85/109 (78%) developed VIPN (TNS©-PV ≥4). Mean TNS©-PV, grading scale, and pain scores were low. CTCAE©-derived grades 3 and 4 sensory and motor VIPN occurred in 1.6%/0%, and 1.9%/0% of subjects, respectively. VIPN did not resolve in months 8-12 despite decreasing dose density. VIPN was worse in older children. Partition cluster analysis revealed 2-3 patient clusters; one cluster (n = 14) experienced severe VIPN. In this population, VIPN occurs more commonly than previous research suggests, persists throughout the first year of treatment, and can be severe.

Keywords: acute lymphoblastic leukemia; children; patterns; severity; vincristine-induced peripheral neuropathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Total Neuropathy Score-Pediatric Vincristine (TNS©-PV) Subjective Symptom Scores in first 12 months (n = 109). (B) TNS©-PV Objective Sign Scores in first 12 months (n = 109).
Figure 2
Figure 2
Total Neuropathy Score-Pediatric Vincristine (TNS©-PV) Mean Total Score and dose density by cluster (n = 109).
Figure 3
Figure 3
Mean Total Neuropathy Score-Pediatric Vincristine (TNS©-PV) Item Scores by cluster (n = 109).

References

    1. American Cancer Society. [Accessed October 25, 2013];Childhood leukemia. 2013 Updated 2013. http://www.cancer.org.
    1. American Cancer Society. [Accessed February 26, 2015];Cancer Facts & Figures 2014. 2014 http://www.cancer.org.
    1. Anghelescu DL, Faughnan LG, Jeha S, Relling MV, Hinds PS, Sandlund JT, Cheng C, Pei D, Hankins G, Pauley JL, Pui C. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57:1147–1153. - PMC - PubMed
    1. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82:51–77. - PubMed
    1. Bisogno G, Ferrari A, Bergeron C, Scagnellato A, Prete A, Alaggio R, Casanova M, D’Angelo P, Di Cataldo A, Carli M. The IVADo regimen - a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European Pediatric Soft Tissue Sarcoma Study Grou. Cancer. 2005;103:1719–1724. - PubMed

Substances